Literature DB >> 26687890

Validating the use of short interfering RNA as a novel technique for cell-specific target gene knockdown in lung ischemia-reperfusion injury.

Heather E Merry1, Patrick Phelan1, Billanna Hwang2, Michael S Mulligan3.   

Abstract

OBJECTIVE: Short interfering RNA is an effective method for target gene knockdown. However, concerns surround the design, administration, efficacy, specificity, and immunostimulatory potential. Although uptake by alveolar macrophages has been demonstrated, studies have not examined its use in lung ischemia-reperfusion injury. We describe the validation of short interference RNA as a novel technique for cell-specific target gene knockdown in our model of lung ischemia-reperfusion injury.
METHODS: Dose-response experiments were performed, and 3 distinct sequences of toll-like receptor-4, toll-like receptor-2, and myeloid differentiation factor-88 short interference RNA were tested for efficacy of knockdown. Saline, lipid vector, and noncoding short interference RNA controls were used. Similar experiments were performed in primary cultures of resident pulmonary cells. Target protein knockdown was assessed by Western blot. Rat serum and cell culture media were assessed for interferon and cytokine production. Biotin labeling was used to assess short interference RNA uptake.
RESULTS: Target protein expression was significantly reduced using short interference RNA. However, toll-like receptor-4 knockdown was isolated to alveolar macrophages, and biotin labeling confirmed toll-like receptor-4 short interference RNA localization to alveolar macrophages. There was significant knockdown of toll-like receptor-4 expression in cultured cells treated with toll-like receptor-4 short interference RNA. There was no significant change in interferon production after short interference RNA treatment. There was effective target protein knockdown with each sequence used.
CONCLUSIONS: Short interference RNA is a valid method for achieving target protein knockdown in alveolar macrophages and is an important tool in the evaluation of its role in the development of lung ischemia-reperfusion injury.
Copyright © 2016 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  TLR2; TLR4; lung reperfusion injury; siRNA

Mesh:

Substances:

Year:  2015        PMID: 26687890      PMCID: PMC4727997          DOI: 10.1016/j.jtcvs.2015.09.125

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  30 in total

1.  Specificity of short interfering RNA determined through gene expression signatures.

Authors:  Dimitri Semizarov; Leigh Frost; Aparna Sarthy; Paul Kroeger; Donald N Halbert; Stephen W Fesik
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-13       Impact factor: 11.205

2.  Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity.

Authors:  Aimee L Jackson; Julja Burchard; Janell Schelter; B Nelson Chau; Michele Cleary; Lee Lim; Peter S Linsley
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

3.  Off-target effects by siRNA can induce toxic phenotype.

Authors:  Yuriy Fedorov; Emily M Anderson; Amanda Birmingham; Angela Reynolds; Jon Karpilow; Kathryn Robinson; Devin Leake; William S Marshall; Anastasia Khvorova
Journal:  RNA       Date:  2006-05-08       Impact factor: 4.942

Review 4.  TLR signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Semin Immunol       Date:  2007-02-01       Impact factor: 11.130

5.  Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes.

Authors:  Luis F Angel; Deborah J Levine; Marcos I Restrepo; Scott Johnson; Edward Sako; Andrea Carpenter; John Calhoon; John E Cornell; Sandra G Adams; Gary B Chisholm; Joe Nespral; Ann Roberson; Stephanie M Levine
Journal:  Am J Respir Crit Care Med       Date:  2006-06-23       Impact factor: 21.405

6.  siRNA-induced caveolin-1 knockdown in mice increases lung vascular permeability via the junctional pathway.

Authors:  Kayo Miyawaki-Shimizu; Dan Predescu; Jun Shimizu; Michael Broman; Sanda Predescu; Asrar B Malik
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-09-23       Impact factor: 5.464

Review 7.  Ischemia-reperfusion-induced lung injury.

Authors:  Marc de Perrot; Mingyao Liu; Thomas K Waddell; Shaf Keshavjee
Journal:  Am J Respir Crit Care Med       Date:  2003-02-15       Impact factor: 21.405

8.  Inhibition of tumor necrosis factor alpha secretion in rat Kupffer cells by siRNA: in vivo efficacy of siRNA-liposomes.

Authors:  Yawu Jing; Andrei Shishkov; Biddanda C Ponnappa
Journal:  Biochim Biophys Acta       Date:  2007-10-02

Review 9.  Inhalable siRNA: potential as a therapeutic agent in the lungs.

Authors:  Niamh Durcan; Charlotte Murphy; Sally-Ann Cryan
Journal:  Mol Pharm       Date:  2008-05-21       Impact factor: 4.939

10.  Effectiveness of siRNA uptake in target tissues by various delivery methods.

Authors:  Shawn D Larson; Lindsey N Jackson; L Andy Chen; Piotr G Rychahou; B Mark Evers
Journal:  Surgery       Date:  2007-08       Impact factor: 3.982

View more
  2 in total

Review 1.  Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part III: Mechanisms: A 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation.

Authors:  Andrew E Gelman; Andrew J Fisher; Howard J Huang; Maher A Baz; Ciara M Shaver; Thomas M Egan; Micheal S Mulligan
Journal:  J Heart Lung Transplant       Date:  2017-07-24       Impact factor: 10.247

Review 2.  Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome.

Authors:  Makhloufi Zoulikha; Qingqing Xiao; George Frimpong Boafo; Marwa A Sallam; Zhongjian Chen; Wei He
Journal:  Acta Pharm Sin B       Date:  2021-08-12       Impact factor: 11.413

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.